OROPHARMA: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
OROPHARMA
Largest movements
- Receivables within one year -€228,795
down €228,795 (-49.3%), from €464,293 to €235,498
of which Trade receivables: -€459,505
- Stocks and contracts +€11,475
up €11,475 (+11.5%), from €99,954 to €111,428
- Other debts -€125,176
no longer reported in 2025 (was €125,176)
- Trade debts -€114,093
down €114,093 (-42.4%), from €269,120 to €155,027
- Profit (loss) carried forward +€19,264
up €19,264, from -€14,122 to €5,142
- Gross operating margin -€29,923
down €29,923 (-59.0%), from €50,719 to €20,797
- Financial income -€11,694
no longer reported in 2025 (was €11,694)
of which Financial income: -€11,694
- Financial charges -€6,068
down €6,068 (-89.0%), from €6,817 to €749
- Other operating charges -€3,883
down €3,883 (-83.2%), from €4,667 to €784
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Cash or the result is not a separate line in both sets of accounts; the cash flow cannot be derived from them.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €572,443 | €352,437 | -€220,005 | -38.4% |
| Fixed assets | 21/28 | €398 | €398 | = | 0.0% |
| Financial fixed assets | 28 | €398 | €398 | = | 0.0% |
| Current assets | 29/58 | €572,045 | €352,039 | -€220,005 | -38.5% |
| Stocks and contracts in progress | 3 | €99,954 | €111,428 | +€11,475 | +11.5% |
| Stocks | 30/36 | €99,954 | €111,428 | +€11,475 | +11.5% |
| Amounts receivable within one year | 40/41 | €464,293 | €235,498 | -€228,795 | -49.3% |
| Trade receivables | 40 | €459,505 | - | -€459,505 | |
| Other amounts receivable | 41 | €4,788 | €235,498 | +€230,710 | +4,819% |
| Deferred charges and accrued income | 490/1 | €7,798 | €5,113 | -€2,685 | -34.4% |
| Total equity and liabilities | 10/49 | €572,443 | €352,437 | -€220,005 | -38.4% |
| Equity | 10/15 | €178,146 | €197,410 | +€19,264 | +10.8% |
| Contributions | 10/11 | €62,000 | €62,000 | = | 0.0% |
| Capital | 10 | €62,000 | €62,000 | = | 0.0% |
| Issued capital | 100 | €62,000 | €62,000 | = | 0.0% |
| Reserves | 13 | €130,268 | €130,268 | = | 0.0% |
| Non-distributable reserves | 130/1 | €6,200 | €6,200 | = | 0.0% |
| Legal reserve | 130 | €6,200 | €6,200 | = | 0.0% |
| Distributable reserves | 133 | €124,068 | €124,068 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€14,122 | €5,142 | +€19,264 | |
| Amounts payable | 17/49 | €394,296 | €155,027 | -€239,269 | -60.7% |
| Amounts payable within one year | 42/48 | €394,296 | €155,027 | -€239,269 | -60.7% |
| Trade debts | 44 | €269,120 | €155,027 | -€114,093 | -42.4% |
| Suppliers | 440/4 | €269,120 | €155,027 | -€114,093 | -42.4% |
| Other amounts payable | 47/48 | €125,176 | - | -€125,176 | |
| Other operating charges | 640/8 | €4,667 | €784 | -€3,883 | -83.2% |
| Gross operating margin | 9900 | €50,719 | €20,797 | -€29,923 | -59.0% |
| Operating profit (loss) | 9901 | €46,053 | €20,013 | -€26,040 | -56.5% |
| Financial income | 75/76B | €11,694 | - | -€11,694 | |
| Recurring financial income | 75 | €11,694 | - | -€11,694 | |
| Non-recurring financial income | 76B | €11,694 | - | -€11,694 | |
| Financial charges | 65/66B | €6,817 | €749 | -€6,068 | -89.0% |
| Recurring financial charges | 65 | €6,817 | €749 | -€6,068 | -89.0% |
| Profit (loss) for the period before taxes | 9903 | €50,929 | €19,264 | -€31,665 | -62.2% |
| Profit (loss) for the period | 9904 | €50,929 | €19,264 | -€31,665 | -62.2% |
| Profit (loss) for the period to be appropriated | 9905 | €50,929 | €19,264 | -€31,665 | -62.2% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 26 October 2026 via checked.be.